Elena Lopez-Knowles1,2, Alex Pearson1, Gene Schuster1,2, Pascal Gellert1,2, Ricardo Ribas1, Belinda Yeo2,3,4, Ros Cutts1, Richard Buus1,2, Isaac Garcia-Murillas1, Ben Haynes2, Lesley-Ann Martin1, Ian Smith3, Nick Turner1,3, Mitch Dowsett5,6. 1. The Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research, London, UK. 2. Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, UK. 3. Breast Unit, Royal Marsden Hospital, London, UK. 4. Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia. 5. The Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research, London, UK. mitch.dowsett@icr.ac.uk. 6. Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, UK. mitch.dowsett@icr.ac.uk.
Abstract
BACKGROUND: Several thousand breast cancer patients develop resistance to aromatase inhibitors (AIs) each year in the UK. Rational treatment requires an improved molecular characterisation of resistant disease. MATERIALS AND METHODS: The mutational landscape of 198 regions in 16 key breast cancer genes and RNA expression of 209 genes covering key pathways was evaluated in paired biopsies before AI treatment and at progression on AI from 48 patients. Validity of findings was assessed in another five ESR1-mutated tumours progressing on AI. RESULTS: Eighty-nine mutations were identified in 41 matched pairs (PIK3CA in 27%; CDH1 in 20%). ESR1 (n = 5), ERBB2 (n = 1) and MAP2K4 (n = 1) had mutations in the secondary sample only. There was very high heterogeneity in gene expression between AI-resistant tumours with few patterns apparent. However, in the ESR1-mutated AI-resistant tumours, expression of four classical oestrogen-regulated genes (ERGs) was sevenfold higher than in ESR1 wild-type tumours, a finding confirmed in the second set of ESR1-mutated tumours. In ESR1 wild-type AI-resistant tumours ERG expression remained suppressed and was uncoupled from the recovery seen in proliferation. CONCLUSIONS: Major genotypic and phenotypic heterogeneity exists between AI-resistant disease. ESR1 mutations appear to drive oestrogen-regulated processes in resistant tumours.
BACKGROUND: Several thousand breast cancerpatients develop resistance to aromatase inhibitors (AIs) each year in the UK. Rational treatment requires an improved molecular characterisation of resistant disease. MATERIALS AND METHODS: The mutational landscape of 198 regions in 16 key breast cancer genes and RNA expression of 209 genes covering key pathways was evaluated in paired biopsies before AI treatment and at progression on AI from 48 patients. Validity of findings was assessed in another five ESR1-mutated tumours progressing on AI. RESULTS: Eighty-nine mutations were identified in 41 matched pairs (PIK3CA in 27%; CDH1 in 20%). ESR1 (n = 5), ERBB2 (n = 1) and MAP2K4 (n = 1) had mutations in the secondary sample only. There was very high heterogeneity in gene expression between AI-resistant tumours with few patterns apparent. However, in the ESR1-mutated AI-resistant tumours, expression of four classical oestrogen-regulated genes (ERGs) was sevenfold higher than in ESR1 wild-type tumours, a finding confirmed in the second set of ESR1-mutated tumours. In ESR1 wild-type AI-resistant tumoursERG expression remained suppressed and was uncoupled from the recovery seen in proliferation. CONCLUSIONS: Major genotypic and phenotypic heterogeneity exists between AI-resistant disease. ESR1 mutations appear to drive oestrogen-regulated processes in resistant tumours.
Authors: Rinath Jeselsohn; Roman Yelensky; Gilles Buchwalter; Garrett Frampton; Funda Meric-Bernstam; Ana Maria Gonzalez-Angulo; Jaime Ferrer-Lozano; Jose A Perez-Fidalgo; Massimo Cristofanilli; Henry Gómez; Carlos L Arteaga; Jennifer Giltnane; Justin M Balko; Maureen T Cronin; Mirna Jarosz; James Sun; Matthew Hawryluk; Doron Lipson; Geoff Otto; Jeffrey S Ross; Addie Dvir; Lior Soussan-Gutman; Ido Wolf; Tamar Rubinek; Lauren Gilmore; Stuart Schnitt; Steven E Come; Lajos Pusztai; Philip Stephens; Myles Brown; Vincent A Miller Journal: Clin Cancer Res Date: 2014-01-07 Impact factor: 12.531
Authors: A S Hamy; I Bieche; J Lehmann-Che; V Scott; Ph Bertheau; J M Guinebretière; M C Matthieu; B Sigal-Zafrani; O Tembo; M Marty; B Asselain; F Spyratos; P de Cremoux Journal: Breast Cancer Res Treat Date: 2016-09-03 Impact factor: 4.872
Authors: D Fumagalli; T R Wilson; R Salgado; X Lu; J Yu; C O'Brien; K Walter; L Y Huw; C Criscitiello; I Laios; V Jose; D N Brown; F Rothé; M Maetens; D Zardavas; P Savas; D Larsimont; M J Piccart-Gebhart; S Michiels; M R Lackner; C Sotiriou; S Loi Journal: Ann Oncol Date: 2016-10 Impact factor: 32.976
Authors: Rita S Mehta; William E Barlow; Kathy S Albain; Ted A Vandenberg; Shaker R Dakhil; Nagendra R Tirumali; Danika L Lew; Daniel F Hayes; Julie R Gralow; Robert B Livingston; Gabriel N Hortobagyi Journal: N Engl J Med Date: 2012-08-02 Impact factor: 91.245
Authors: Elena López-Knowles; Corrinne V Segal; Qiong Gao; Isaac Garcia-Murillas; Nicholas C Turner; Ian Smith; Lesley-Ann Martin; Mitch Dowsett Journal: Breast Cancer Res Date: 2014-06-30 Impact factor: 6.466
Authors: Xiaoyong Fu; Chad J Creighton; Nrusingh C Biswal; Vijetha Kumar; Martin Shea; Sabrina Herrera; Alejandro Contreras; Carolina Gutierrez; Tao Wang; Sarmistha Nanda; Mario Giuliano; Gladys Morrison; Agostina Nardone; Kristen L Karlin; Thomas F Westbrook; Laura M Heiser; Pavana Anur; Paul Spellman; Sylvie M Guichard; Paul D Smith; Barry R Davies; Teresa Klinowska; Adrian V Lee; Gordon B Mills; Mothaffar F Rimawi; Susan G Hilsenbeck; Joe W Gray; Amit Joshi; C Kent Osborne; Rachel Schiff Journal: Breast Cancer Res Date: 2014-09-11 Impact factor: 6.466
Authors: Weiyi Toy; Yang Shen; Helen Won; Bradley Green; Rita A Sakr; Marie Will; Zhiqiang Li; Kinisha Gala; Sean Fanning; Tari A King; Clifford Hudis; David Chen; Tetiana Taran; Gabriel Hortobagyi; Geoffrey Greene; Michael Berger; José Baselga; Sarat Chandarlapaty Journal: Nat Genet Date: 2013-11-03 Impact factor: 38.330
Authors: Sean W Fanning; Christopher G Mayne; Venkatasubramanian Dharmarajan; Kathryn E Carlson; Teresa A Martin; Scott J Novick; Weiyi Toy; Bradley Green; Srinivas Panchamukhi; Benita S Katzenellenbogen; Emad Tajkhorshid; Patrick R Griffin; Yang Shen; Sarat Chandarlapaty; John A Katzenellenbogen; Geoffrey L Greene Journal: Elife Date: 2016-02-02 Impact factor: 8.140
Authors: Mary J Laws; Yvonne Ziegler; Sayyed Hamed Shahoei; Parama Dey; Sung Hoon Kim; Mayuri Yasuda; Ben Ho Park; Kendall W Nettles; John A Katzenellenbogen; Erik R Nelson; Benita S Katzenellenbogen Journal: Breast Cancer Res Treat Date: 2020-04-10 Impact factor: 4.872
Authors: Milana A Bergamino; Elena López-Knowles; Gabriele Morani; Holly Tovey; Lucy Kilburn; Eugene F Schuster; Anastasia Alataki; Margaret Hills; Hui Xiao; Chris Holcombe; Anthony Skene; John F Robertson; Ian E Smith; Judith M Bliss; Mitch Dowsett; Maggie C U Cheang Journal: EBioMedicine Date: 2022-08-16 Impact factor: 11.205